Jefferies maintained a Buy rating on Surgery Partners, Inc. (SGRY) on March 4, 2026. The move kept analyst conviction while lowering the price target to $16.25, a change that pressured the stock intraday. The phrase SGRY analyst rating matters because three major firms reiterated positive stances the same day, balancing optimism about the recovery with caution on 2026 guidance. Investors should note the mix of maintained ratings and price target cuts when sizing positions.

Analyst actions and timeline for SGRY analyst rating

Three analysts issued maintained ratings on March 4, 2026. Jefferies at 12:12 PM maintained Buy and lowered its price target to $16.25. Cantor Fitzgerald at 09:28 AM reiterated Overweight. RBC Capital at 08:04 AM kept Outperform while trimming its target after guidance concerns.

Each firm kept a positive stance rather than cutting to neutral or sell. That shows continued industry confidence in Surgery Partners, Inc. despite near-term headwinds.

Price targets, guidance and cited catalysts for SGRY analyst rating

Jefferies explicitly lowered the price target to $16.25, citing updated assumptions after the Q4 call and 2026 guide. RBC also trimmed its target and linked the revision to the 2026 revenue and margin outlook published in the earnings release. We reviewed the Jefferies note on StreetInsider source and the company call context in a Seeking Alpha transcript source.

Analysts cited payer mix shifts and slower same-facility growth as the primary drivers behind the target cuts.

What the maintained ratings mean for investors

A maintained rating signals that analysts still expect outperformance versus peers, though at reduced upside. A cut in price target with a maintained Buy or Overweight shows the firm expects recovery but at a lower near-term valuation.

For investors this means risk and reward both narrowed: downside protection from positive analyst views remains, but upside is smaller with the new targets. Use position sizing and watch guidance execution.

Historical analyst coverage and trend for Surgery Partners, Inc. analyst rating

Surgery Partners has carried steady coverage from Bulge Bracket and middle-market firms since 2022. The March 4, 2026 actions continue a pattern of maintained positive ratings with periodic target resets tied to guides.

Analyst consensus has shifted slowly lower on targets after each earnings cycle, reflecting macro and payer pressures. Market cap stands at $1,821,132,248, keeping SGRY in the small-cap healthcare services peer group.

Stock reaction and short-term market impact of the SGRY analyst rating moves

StreetInsider summaries show mixed intraday moves. Two entries list a -2.19% (-$0.31) change since coverage publication. RBC’s note coincided with a +1.15% (+$0.16) intraday move in one report. These small moves reflect target changes more than rating withdrawals.

Investors should watch volume and follow-up comments. Maintained positive ratings can limit heavy selling, but repeated target cuts can weigh on sentiment over weeks.

Meyka grade and AI-powered view on SGRY analyst rating

Meyka AI rates SGRY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ reflects solid operational recovery potential and valuation pressure from guidance cuts.

Meyka AI is an AI-powered market analysis platform. These grades are not guaranteed and we are not financial advisors. Investors should combine this grade with their own research and risk tolerance.

Final Thoughts

On March 4, 2026 three firms maintained positive stances on Surgery Partners, Inc., with Jefferies keeping a Buy and lowering its price target to $16.25. Cantor Fitzgerald reiterated Overweight and RBC Capital stayed at Outperform while trimming its target after the 2026 guide. The cluster of maintained ratings signals continued analyst confidence in the company’s medium-term recovery, even as near-term revenue and payer-mix concerns compress upside. For investors, the immediate implication is tempered upside but a base of analyst support. Monitor execution against the $3.35B–$3.45B 2026 revenue guide, upcoming quarters for margin recovery, and any further price target revisions. Use the Meyka grade B+ as one input, and place weight on guidance execution and cash flow trends before changing core exposure to SGRY.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.